Research
Hormonal
Accelerated gastric emptying in overweight and obese individuals may contribute to rapid postprandial glucose increases and insulin resistance.
For those with obesity, managing gastric emptying through dietary choices (e.g., fiber) might help stabilize blood sugar. However, more research is needed to confirm this link.
LimitedQualifiesLOW confidence
a recent, large-scale cross-sectional analysis reported faster GE rates measured via scintigraphy and reduced fasting plasma PYY concentrations in overweight and obese compared to lean adults [27]. Therefore, it is intriguing to speculate that accelerated GE in obesity may lead to rapid increase in blood glucose, thus imposing a constant challenge to postprandial glucose homeostasis.
Why this rating
The paper notes that data on altered GE rates in obesity is inconclusive due to methodology differences.
Source
Gastrointestinal Transit Time, Glucose Homeostasis and Metabolic Health: Modulation by Dietary Fibers
Mattea Müller et al. · Nutrients · 2018
DOI 10.3390/nu10030275
narrative_reviewCited 321×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Dietary fiber intake modulates gastrointestinal transit time, which serves as a key mechanism for improving glucose homeostasis and reducing the risk of metabolic diseases like obesity and type 2 diabetes.Moderate
- Viscous soluble fibers (e.g., beta-glucans, pectin, psyllium) delay gastric emptying, which contributes to reduced postprandial glucose concentrations and improved insulin sensitivity.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →